Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

Summary

This is a single-center, phase 2 randomized clinical trial of tamoxifen on mean percent predicted isometric muscle strength in patients with amyotrophic lateral sclerosis (ALS). The purpose is to determine whether the triphenylethylenetamoxifen, used as adjuvant therapy in the treatment of breast cancer, can delay the loss of isometric muscle strength in ALS patients.

Timeline

Start

2001-01

Primary completion

—

Completion

2005-01

Drugs

Indications